Company News: Celgene and Abraxis BioScience

Share this article:
New Jersey-based biotech Celgene announced an agreement to purchase Abraxis BioScience, a biotech focused on cancer treatments, for $2.9 billion. Abraxis BioScience markets Abraxane, a chemotherapy treatment option for metastatic breast cancer, which netted $314.5 million in 2009, down from $335.6 in 2008, according to an Abraxis annual report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.